来自MSN8 天
Amgen’s Imdylltra wins conditional MHRA licence for lung cancer
Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.
Pharmaceutical Technology9 天
Sacituzumab tirumotecan by Merck for Peritoneal Cancer: Likelihood of Approval
Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Peritoneal Cancer.
Pharmaceutical Technology9 天
Sotorasib by Amgen for Solid Tumor: Likelihood of Approval
Sotorasib is under clinical development by Amgen and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) ...
C&EN1 个月
Synthesis, Characterization, and Control Strategies for Cabazitaxel-Related Substances at Scale
Department of Chemistry, Faculty of Engineering and Technology, SRM Institute of Science and Technology, Kattankulathur, Chennai 603203, Tamil Nadu, India ...
Medscape1 个月
Europe Approves Its First Drug for Von Hippel-Lindau Tumors
The drug is an antineoplastic agent that acts by blocking the activity of hypoxia-inducible factor 2 alpha (HIF-2α), which regulates cellular proliferation, angiogenesis, and tumor growth.